Table 2.

Stakeholder interview emerging theme areas: challenges to the consent process, and opportunities for Dynamic Consent.

Challenge	Opportunity for Dynamic Consent
Arranging appointments.	One interviewee estimated >90% patients prefer to arrange appointments via email, indicating study participants have a level of comfort with and access to technology.
The genetic counsellor and clinicians explain genomics by using their own phone to show videos.	Standardise the use of technology in health and digital resources.
It is important to tailor the consent discussion to the family, based on their motivations for having the testing and expectations.	De-prioritise sections of text that aren’t relevant to the patient, while providing a means to access the information at a later time.
If results are negative, it is left up to the patient to follow-up on what to do next.	Tailored and trusted information provided to participants that covers their whole research journey in one place.
Participants need to be able to make changes to their involvement in a study without contacting the genetic counsellor every time.	Easy access to the details of study participation and managing levels participation.
Keeping participants involved and motivated to do follow-up surveys.	Patient engagement through opportunities for ongoing interaction with the study. Digital reminders.
Consent forms are long and the language too difficult.	Online delivery formats can condense information. Online glossaries.
Participants need to get information at the right time, for example the different types of results explained just before receiving results.	Participants can return to review study information at any time.
Participants need time frames and an ability to check in with the study.	Two-way contact with researchers. Communication of study timelines, for example sample tracking.
Genetic reports are difficult to understand.	Online access to reports to promote discussion with health professionals.
Consent information is different between different studies. Participants do not read the consent form, they rely on the genetic counsellor to explain it.	Promote consistent presentation and language.
Tracking symptoms.	Patient reported outcomes.
Having access to support groups and information.	Providing participants with information and support from trusted sources.
Patients do not look at the consent form and probably do not understand the information. They base their decision to consent on trust in their doctor.	User friendly, interactive formats and organisation of information.
The ideal consent form would be 2–3 pages.	Organising study information in ways participants can focus on information that is priority for them.
Consent forms are difficult for non-English speakers. Downloading an app is another potential barrier.	Language translations and IT guides.